カテゴリ： GlobalData, アメリカ, 企業調査

Sorrento Therapeutics Inc (SRNE)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Sorrento Therapeutics Inc (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8033
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：104
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sorrento Therapeutics Inc (STI), formerly QuikByte Software Inc, is a cancer therapeutic service provider. The company offers CD38 CAR-T, lidocaine topical system, resiniferatoxin. Its product pipeline includes CD38 CAR-T, CEA CAR-T, CD38 ADC and seprehvir. STI provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. The company offers therapies for immune oncology, pain management and ark animal health. It offers G-MAB technology, CAR-T, ADCs, iTAbs, oncolytic virus. STI offers research and development and clinical trials. The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. STI is headquartered in San Diego, California, the US.

Sorrento Therapeutics Inc (SRNE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Sorrento Therapeutics Acquires Sofusa Platform from Kimberly-Clark 17
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 18
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 19
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 20
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 21
Venture Financing 22
Celularity Raises USD250 Million in Venture Financing 22
Celularity Raises Funds through Series A Financing 24
Scilex Pharma Raises USD0.5 Million in Financing 25
Globavir Biosciences Secures USD4 Million in Venture Funding 26
Scilex Pharma Raises US$5 Million In Venture Financing 27
Partnerships 28
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 28
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 29
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 31
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 32
Sorrento Therapeutics Forms Joint Venture with Yuhan 33
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 34
Sorrento Therapeutics forms Joint Venture with City of Hope 35
Sorrento Therapeutics and NantBioscience Form Joint Venture 36
Advaxis Enters into Research Agreement with Sorrento Therapeutics 37
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 38
NantWorks to Form Joint Venture with Sorrento Therapeutics 39
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 40
Licensing Agreements 41
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 41
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 42
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 43
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 44
NantWorks Enters into Licensing Agreement with Sorrento Therapeutics 45
NantCell Enters into Licensing Agreement with Sorrento Therapeutics 46
Sorrento Therapeutics Enters into Licensing Agreement with Lee’s Pharma for Anti-PD-L1 Antibody 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 49
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 50
Equity Offering 51
Sorrento Therapeutics Files Registration Statement to Raise up to USD269 Million in Public Offering of Shares 51
Sorrento Therapeutics to Raise up to USD100 Million in Public Offering of Shares 52
Sorrento Therapeutics Plans to Raise Funds through Private Placement of Shares 53
Sorrento Therapeutics to Raise Funds through Public Offering of Shares 54
Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 55
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 57
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 58
Sorrento Therapeutics Raises USD28.8 million in Public Offering of Shares 60
Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 62
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 63
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 65
Debt Offering 66
Scilex Pharma Raises USD140 Million in Private Placement of Notes Due 2026 66
Sorrento Therapeutics to Raise USD120.5 Million in Private Placement of 5% Notes 67
Sorrento Therapeutics Raises USD50 Million in Private Placement of 5% Notes and Warrants 68
Sorrento Therapeutics Raises USD1.9 Million in Public Offering of Notes 69
Asset Transactions 70
Celularity Acquires Assets from TNK Therapeutics 70
Acquisition 71
TNK Therapeutics Acquires Virttu Biologics 71
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 72
TNK Therapeutics Acquires Two Biotechnology Companies 73
NantPharma Acquires IgDraSol from Sorrento Therapeutics 74
Itochu Chemical Frontier Invests in Scilex Pharma 75
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 76
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 77
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 78
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 79
Sorrento Therapeutics Inc – Key Competitors 81
Sorrento Therapeutics Inc – Key Employees 82
Sorrento Therapeutics Inc – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Joint Venture 84
Recent Developments 85
Strategy And Business Planning 85
May 04, 2017: Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business 85
Corporate Communications 86
Mar 19, 2018: Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 86
Oct 02, 2017: Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors 87
Legal and Regulatory 88
Jun 14, 2017: Sorrento Therapeutics Announces Dismissal Of Lawsuits 88
Product News 89
Aug 21, 2017: Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform 89
06/14/2017: Sorrento Therapeutics’ Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido 90
02/28/2018: Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain 91
01/09/2017: Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido 93
Product Approvals 94
Nov 14, 2017: Scilex Pharmaceuticals, Sorrento Therapeutics Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido 94
Aug 29, 2017: Sorrento Therapeutics Submits NDA For ZTlido Next-Generation Lidocaine Patch 95
Jun 29, 2017: Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain 96
Clinical Trials 97
Sep 07, 2018: Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation 97
Feb 05, 2018: Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea 99
Jan 29, 2018: China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody 100
Other Significant Developments 101
Mar 28, 2018: Sorrento Therapeutics Chairman/CEO update to stockholders 101
Feb 05, 2018: Sorrento Therapeutics Chairman/CEO letter to stockholders 102
Appendix 104
Methodology 104
About GlobalData 104
Contact Us 104
Disclaimer 104

List of Tables
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sorrento Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Sorrento Therapeutics Acquires Sofusa Platform from Kimberly-Clark 17
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 18
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 19
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 20
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 21
Celularity Raises USD250 Million in Venture Financing 22
Celularity Raises Funds through Series A Financing 24
Scilex Pharma Raises USD0.5 Million in Financing 25
Globavir Biosciences Secures USD4 Million in Venture Funding 26
Scilex Pharma Raises US$5 Million In Venture Financing 27
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 28
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 29
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 31
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 32
Sorrento Therapeutics Forms Joint Venture with Yuhan 33
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 34
Sorrento Therapeutics forms Joint Venture with City of Hope 35
Sorrento Therapeutics and NantBioscience Form Joint Venture 36
Advaxis Enters into Research Agreement with Sorrento Therapeutics 37
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 38
NantWorks to Form Joint Venture with Sorrento Therapeutics 39
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 40
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 41
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 42
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 43
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 44
NantWorks Enters into Licensing Agreement with Sorrento Therapeutics 45
NantCell Enters into Licensing Agreement with Sorrento Therapeutics 46
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 49
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 50
Sorrento Therapeutics Files Registration Statement to Raise up to USD269 Million in Public Offering of Shares 51
Sorrento Therapeutics to Raise up to USD100 Million in Public Offering of Shares 52
Sorrento Therapeutics Plans to Raise Funds through Private Placement of Shares 53
Sorrento Therapeutics to Raise Funds through Public Offering of Shares 54
Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 55
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 57
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 58
Sorrento Therapeutics Raises USD28.8 million in Public Offering of Shares 60
Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 62
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 63
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 65
Scilex Pharma Raises USD140 Million in Private Placement of Notes Due 2026 66
Sorrento Therapeutics to Raise USD120.5 Million in Private Placement of 5% Notes 67
Sorrento Therapeutics Raises USD50 Million in Private Placement of 5% Notes and Warrants 68
Sorrento Therapeutics Raises USD1.9 Million in Public Offering of Notes 69
Celularity Acquires Assets from TNK Therapeutics 70
TNK Therapeutics Acquires Virttu Biologics 71
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 72
TNK Therapeutics Acquires Two Biotechnology Companies 73
NantPharma Acquires IgDraSol from Sorrento Therapeutics 74
Itochu Chemical Frontier Invests in Scilex Pharma 75
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 76
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 77
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 78
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 79
Sorrento Therapeutics Inc, Key Competitors 81
Sorrento Therapeutics Inc, Key Employees 82
Sorrento Therapeutics Inc, Subsidiaries 83
Sorrento Therapeutics Inc, Joint Venture 84

List of Figures
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Sorrento Therapeutics Inc (SRNE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Arix Bioscience PLC (ARIX)-製薬・医療分野：企業M&A・提携分析
    Summary Arix Bioscience PLC (Arix Bioscience), formerly Arix Bioscience Ltd, is a healthcare and life science company. It offers financing and operational and strategic direction for the companies to support their businesses. The company’s expertise spans in various areas which include academic scie …
  • Meketa Investment Group：企業の戦略・SWOT・財務情報
    Meketa Investment Group - Strategy, SWOT and Corporate Finance Report Summary Meketa Investment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Erin Energy Corp (ERN)：企業の財務・戦略的SWOT分析
    Summary Erin Energy Corp (Erin Energy), formerly CAMAC Energy Inc, a subsidiary of CAMAC Energy Holdings Ltd, is an oil and gas company that develops and produces oil and gas assets. The company's portfolio includes seven licenses in four countries and covers an area of approximately 19,000 sq km of …
  • BBX Capital Corporation：企業のM&A・事業提携・投資動向
    BBX Capital Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BBX Capital Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Range Resources Ltd (RRS)：企業の財務・戦略的SWOT分析
    Range Resources Ltd (RRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • New Image Group Ltd：企業の戦略的SWOT分析
    New Image Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • MetaStat Inc (MTST)：医療機器：M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Osiris Therapeutics Inc (OSIR)：企業の財務・戦略的SWOT分析
    Osiris Therapeutics Inc (OSIR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Centers for Disease Control and Prevention-製薬・医療分野：企業M&A・提携分析
    Summary Centers for Disease Control and Prevention (CDC), a subsidiary of US Department of Health and Human Services is a public health institute that offers health, safety and security threat management solutions. The institute provides health information to fight diseases and support communities f …
  • ProQR Therapeutics NV (PRQR)：製薬・医療：M&Aディール及び事業提携情報
    Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide …
  • Mentor Graphics Corporation：企業の戦略・SWOT・財務分析
    Mentor Graphics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mentor Graphics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TE Connectivity Ltd (TEL)：電力：M&Aディール及び事業提携情報
    Summary TE Connectivity Ltd (TE Connectivity), formerly Tyco Electronics Ltd, is a technology company. It designs and manufactures connectivity and sensor solutions. The company offers connectors; sensors; relays; heat shrink tubing; wire and cable; antennas and circuit protection devices. Its solut …
  • Shenandoah Valley Electric Cooperative Inc：企業の戦略的SWOT分析
    Shenandoah Valley Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Eurofins Scientific SE (ERF)：製薬・医療：M&Aディール及び事業提携情報
    Summary Eurofins Scientific SE (Eurofins) is a life sciences company, which provides a range of analytical testing services to clients in various industries. The company offers food and feed testing, biopharma services, pharma discovery services, genomic pharma services, pharma early development, ph …
  • Tissue Regenix Ltd：企業の製品パイプライン分析
    Summary Tissue Regenix Ltd (Tissue Regenix), a subsidiary of Tissue Regenix Group PLC, is a medical technology company that offers replacement body parts from biological materials by using the dCELL technology platform. The company’s proprietary dCELL technology process is applied in markets such as …
  • Mckinsey & Company, Inc.
    Mckinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mckinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • BioVectra Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary BioVectra Inc (BioVectra), a subsidiary of Mallinckrodt Plc, is a contract development and manufacturing organization that offers cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. The organization's products include bioprocessing reagents, diagnostic reagent …
  • Toei Animation Co., Ltd.：企業の戦略・SWOT・財務分析
    Toei Animation Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toei Animation Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Asian Citrus Holdings Ltd (73)：企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Vigo Coal Company Incorporated：企業の戦略・SWOT・財務情報
    Vigo Coal Company Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vigo Coal Company Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆